Avalo Therapeutics Inc Financials

AVTX

Key Financial Metrics

Revenue

$441K

YoY-77.1%

5Y CAGR-42.1%

Avalo Therapeutics Inc generated $441K in revenue in fiscal year 2024. This represents a decrease of 77.1% from the prior year.

EBITDA

-$68.3M

YoY-151.3%

Avalo Therapeutics Inc's EBITDA was -$68.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 151.3% from the prior year.

Free Cash Flow

N/A

Net Income

-$35.1M

YoY-11.4%

Avalo Therapeutics Inc reported -$35.1M in net income in fiscal year 2024. This represents a decrease of 11.4% from the prior year.

EPS (Diluted)

$-20.91

YoY+81.6%

Avalo Therapeutics Inc earned $-20.91 per diluted share in fiscal year 2024. This represents an increase of 81.6% from the prior year.

Cash & Debt

$134.5M

YoY+1714.5%

5Y CAGR+106.2%

10Y CAGR+27.6%

Avalo Therapeutics Inc held $134.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

10M

YoY+1206.1%

5Y CAGR-25.1%

10Y CAGR+32.0%

Avalo Therapeutics Inc had 10M shares outstanding in fiscal year 2024. This represents an increase of 1206.1% from the prior year.

Gross Margin

N/A

Operating Margin

-15535.6%

YoY-14114.0pp

5Y CAGR-15296.5pp

Avalo Therapeutics Inc's operating margin was -15535.6% in fiscal year 2024, reflecting core business profitability. This is down 14114.0 percentage points from the prior year.

Net Margin

-7965.8%

YoY-6326.3pp

5Y CAGR-7727.7pp

Avalo Therapeutics Inc's net profit margin was -7965.8% in fiscal year 2024, showing the share of revenue converted to profit. This is down 6326.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$24.4M

YoY+77.3%

5Y CAGR+15.7%

10Y CAGR+7.2%

Avalo Therapeutics Inc invested $24.4M in research and development in fiscal year 2024. This represents an increase of 77.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

AVTX Income Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Revenue	$441K-77.1%	$1.9M-89.3%	$18.1M+234.4%	$5.4M-19.4%	$6.7M-0.8%	$6.8M
Cost of Revenue	N/A	$1.3M-62.6%	$3.4M+130.3%	$1.5M+397.0%	$300K+153.0%	-$567K
Gross Profit	N/A	$640K-95.6%	$14.6M+274.1%	$3.9M-38.9%	$6.4M	N/A
R&D Expenses	$24.4M+77.3%	$13.8M-56.0%	$31.3M-47.7%	$59.8M+85.9%	$32.2M+173.7%	$11.8M
SG&A Expenses	$17.2M+67.4%	$10.3M-50.3%	$20.7M-16.0%	$24.7M+41.6%	$17.4M+72.1%	$10.1M
Operating Income	-$68.5M-150.5%	-$27.4M+26.9%	-$37.4M+54.4%	-$82.1M-12.8%	-$72.8M-351.4%	-$16.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$114K+714.3%	$14K-50.0%	$28K+114.3%	-$196K+93.0%	-$2.8M-1096.4%	$280K
Net Income	-$35.1M-11.4%	-$31.5M+24.3%	-$41.7M+50.6%	-$84.4M-32.9%	-$63.5M-295.1%	-$16.1M
EPS (Diluted)	$-20.91+81.6%	$-113.58+89.3%	$-1063.00	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'24	Q1'24	Q4'24
Revenue	$0	N/A	N/A	N/A	$249K	$0	$0	N/A
Cost of Revenue	N/A	$0	N/A	N/A	-$714K-308.2%	$343K+528.8%	-$80K	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	-$343K	N/A	N/A
R&D Expenses	$13.6M-3.2%	$14.1M+54.3%	$9.1M	N/A	$9.5M+107.3%	$4.6M+117.4%	$2.1M	N/A
SG&A Expenses	$5.6M+6.4%	$5.2M-5.5%	$5.5M	N/A	$4.3M-5.3%	$4.5M+41.8%	$3.2M	N/A
Operating Income	-$19.2M+0.6%	-$19.3M-31.7%	-$14.7M	N/A	-$12.9M-34.3%	-$9.6M+70.8%	-$32.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$11K-31.3%	$16K+100.0%	$8K	N/A	-$14K-300.0%	$7K0.0%	$7K	N/A
Net Income	-$30.6M-47.5%	-$20.8M-57.9%	-$13.1M	N/A	$23.0M-76.6%	$98.5M+181.2%	-$121.3M	N/A
EPS (Diluted)	$-2.19-14.1%	$-1.92-53.6%	$-1.25	N/A	$-2.83+79.9%	$-14.07+90.0%	$-141.14	N/A

AVTX Balance Sheet

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Total Assets	$150.7M+618.0%	$21.0M-37.1%	$33.4M-58.4%	$80.2M+83.3%	$43.8M+21.2%	$36.1M
Current Assets	$138.9M+1554.4%	$8.4M-48.9%	$16.4M-73.5%	$61.8M+137.8%	$26.0M+46.7%	$17.7M
Cash & Equivalents	$134.5M+1714.5%	$7.4M-43.7%	$13.2M-75.9%	$54.6M+188.5%	$18.9M+424.2%	$3.6M
Inventory	N/A	$0-100.0%	$20K-47.4%	$38K+1166.7%	$3K-85.9%	$21K
Accounts Receivable	N/A	N/A	$0-100.0%	$1.1M-51.3%	$2.2M+117.3%	$1.0M
Goodwill	$10.5M0.0%	$10.5M-27.1%	$14.4M0.0%	$14.4M0.0%	$14.4M0.0%	$14.4M
Total Liabilities	$17.7M+29.3%	$13.7M-69.1%	$44.3M-22.5%	$57.1M+197.7%	$19.2M+27.0%	$15.1M
Current Liabilities	$7.0M+50.7%	$4.6M-79.1%	$22.1M+11.2%	$19.9M+30.6%	$15.2M+25.2%	$12.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$133.0M+1721.4%	$7.3M+166.9%	-$10.9M-147.3%	$23.1M-6.0%	$24.6M+17.0%	$21.0M
Retained Earnings	-$370.3M-10.5%	-$335.1M-10.3%	-$303.8M-15.9%	-$262.2M-47.5%	-$177.8M-55.6%	-$114.3M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'24	Q1'24	Q4'24
Total Assets	$125.1M-1.2%	$126.6M-8.6%	$138.5M-8.1%	$150.7M+53.1%	$98.5M-9.1%	$108.3M-12.5%	$123.7M+489.4%	$21.0M
Current Assets	$113.8M-1.2%	$115.2M-9.3%	$126.9M-8.6%	$138.9M+61.2%	$86.1M-10.2%	$95.9M-13.8%	$111.2M+1224.8%	$8.4M
Cash & Equivalents	$27.0M-36.2%	$42.3M-66.2%	$125.0M-7.1%	$134.5M+64.4%	$81.9M-12.4%	$93.4M-15.2%	$110.2M+1385.9%	$7.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M0.0%	$10.5M
Total Liabilities	$33.6M+52.5%	$22.0M+38.4%	$15.9M-10.1%	$17.7M-76.6%	$75.7M-31.4%	$110.5M-50.9%	$224.8M+1542.3%	$13.7M
Current Liabilities	$8.0M-13.9%	$9.3M+64.9%	$5.6M-19.3%	$7.0M-88.5%	$60.7M-37.1%	$96.4M-55.3%	$215.7M+4570.9%	$4.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$91.5M-12.5%	$104.6M-14.7%	$122.6M-7.8%	$133.0M+531.2%	$21.1M+254.9%	-$13.6M+87.9%	-$112.5M-1640.8%	$7.3M
Retained Earnings	-$434.8M-7.6%	-$404.2M-5.4%	-$383.4M-3.6%	-$370.3M-10.6%	-$334.9M+6.4%	-$358.0M+21.6%	-$456.4M-36.2%	-$335.1M

AVTX Cash Flow Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$49.1M-59.9%	-$30.7M-14.7%	-$26.8M+62.3%	-$70.9M-74.9%	-$40.5M-111.9%	-$19.1M
Capital Expenditures	N/A	N/A	$95K-15.9%	$113K+79.4%	$63K-76.0%	$262K
Free Cash Flow	N/A	N/A	-$26.8M+62.2%	-$71.0M-74.9%	-$40.6M-109.3%	-$19.4M
Investing Cash Flow	$356K+367.7%	-$133K-40.0%	-$95K+15.9%	-$113K-101.0%	$11.1M+2612.9%	-$443K
Financing Cash Flow	$175.8M+602.2%	$25.0M+270.4%	-$14.7M-113.8%	$106.8M+138.4%	$44.8M+256.6%	$12.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'24	Q1'24	Q4'24
Operating Cash Flow	N/A	N/A	-$9.5M	N/A	N/A	N/A	-$6.2M	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$0	N/A	N/A	N/A	$356K	N/A
Financing Cash Flow	N/A	N/A	$0	N/A	N/A	N/A	$108.6M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AVTX Financial Ratios

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	33.3%-47.7pp	81.0%+8.6pp	72.4%-23.1pp	95.5%	N/A
Operating Margin	-15535.6%-14114.0pp	-1421.6%-1214.2pp	-207.4%+1314.2pp	-1521.6%-434.2pp	-1087.4%-848.3pp	-239.1%
Net Margin	-7965.8%-6326.3pp	-1639.5%-1408.7pp	-230.8%+1332.3pp	-1563.1%-615.2pp	-947.9%-709.8pp	-238.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-23.3%+126.9pp	-150.3%-25.4pp	-124.8%-19.7pp	-105.2%+39.9pp	-145.1%-100.6pp	-44.5%
Current Ratio	19.96+18.1	1.82+1.1	0.74-2.4	3.11+1.4	1.71+0.3	1.46
Debt-to-Equity	0.13-1.7	1.87+5.9	-4.06-6.5	2.48+1.7	0.78+0.1	0.72
FCF Margin	N/A	N/A	-148.7%+1166.7pp	-1315.4%-709.3pp	-606.1%-318.8pp	-287.3%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'24	Q1'24	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-5165.1%	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	9251.8%	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	109.3%	N/A	N/A	N/A
Return on Assets	-24.5%-8.1pp	-16.4%-6.9pp	-9.5%	N/A	23.4%-67.5pp	90.9%+188.9pp	-98.0%	N/A
Current Ratio	14.28+1.8	12.44-10.2	22.61+2.7	19.96+18.5	1.42+0.4	0.99+0.5	0.52-1.3	1.82
Debt-to-Equity	0.37+0.2	0.21+0.1	0.130.0	0.13-3.5	3.59+11.7	-8.12-6.1	-2.00-3.9	1.87
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is Avalo Therapeutics Inc's annual revenue?

Avalo Therapeutics Inc (AVTX) reported $441K in revenue for fiscal year 2024.

How fast is Avalo Therapeutics Inc's revenue growing?

Avalo Therapeutics Inc (AVTX) revenue declined by 77.1% year-over-year, from $1.9M to $441K in fiscal year 2024.

Is Avalo Therapeutics Inc profitable?

No, Avalo Therapeutics Inc (AVTX) reported a net income of -$35.1M in fiscal year 2024, with a net profit margin of -7965.8%.

What is Avalo Therapeutics Inc's earnings per share (EPS)?

Avalo Therapeutics Inc (AVTX) reported diluted earnings per share of $-20.91 for fiscal year 2024.

What is Avalo Therapeutics Inc's EBITDA?

Avalo Therapeutics Inc (AVTX) had EBITDA of -$68.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Avalo Therapeutics Inc's operating margin?

Avalo Therapeutics Inc (AVTX) had an operating margin of -15535.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Avalo Therapeutics Inc's net profit margin?

Avalo Therapeutics Inc (AVTX) had a net profit margin of -7965.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Avalo Therapeutics Inc's operating cash flow?

Avalo Therapeutics Inc (AVTX) generated -$49.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Avalo Therapeutics Inc's total assets?

Avalo Therapeutics Inc (AVTX) had $150.7M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Avalo Therapeutics Inc spend on research and development?

Avalo Therapeutics Inc (AVTX) invested $24.4M in research and development during fiscal year 2024.

How many shares does Avalo Therapeutics Inc have outstanding?

Avalo Therapeutics Inc (AVTX) had 10M shares outstanding as of fiscal year 2024.

What is Avalo Therapeutics Inc's current ratio?

Avalo Therapeutics Inc (AVTX) had a current ratio of 19.96 as of fiscal year 2024, which is generally considered healthy.

What is Avalo Therapeutics Inc's debt-to-equity ratio?

Avalo Therapeutics Inc (AVTX) had a debt-to-equity ratio of 0.13 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Avalo Therapeutics Inc's return on assets (ROA)?

Avalo Therapeutics Inc (AVTX) had a return on assets of -23.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.